Parkside Advisors LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Parkside Advisors LLC purchased a new position in Pfizer Inc. (NYSE:PFE – Get Rating) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,353 shares of the biopharmaceutical company’s stock, valued at approximately $377,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Pfizer by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock worth $21,599,270,000 after purchasing an additional 5,139,634 shares in the last quarter. Northern Trust Corp grew its stake in Pfizer by 0.7% during the 2nd quarter. Northern Trust Corp now owns 66,978,348 shares of the biopharmaceutical company’s stock valued at $3,511,675,000 after acquiring an additional 467,468 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 13.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock valued at $3,097,341,000 after acquiring an additional 6,972,650 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Pfizer by 0.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 56,659,179 shares of the biopharmaceutical company’s stock valued at $2,479,407,000 after acquiring an additional 317,858 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Pfizer by 3.2% during the 2nd quarter. Legal & General Group Plc now owns 42,791,672 shares of the biopharmaceutical company’s stock valued at $2,243,574,000 after acquiring an additional 1,336,403 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. SVB Leerink lowered their target price on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on Pfizer in a research note on Tuesday, February 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research note on Wednesday, February 1st. Credit Suisse Group lowered their price target on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Finally, Barclays lowered their price target on Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $50.38.

Pfizer Stock Down 0.7 %

PFE opened at $40.10 on Friday. The business has a 50 day moving average price of $43.26 and a 200 day moving average price of $46.03. Pfizer Inc. has a twelve month low of $39.23 and a twelve month high of $56.32. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. The firm has a market cap of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. During the same period in the previous year, the company earned $1.08 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 3.33 EPS for the current year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.